|
Online edition of India's National Newspaper Thursday, June 28, 2001 |
|
Front Page |
National |
Southern States |
Other States |
International |
Opinion |
Business |
Sport |
Science & Tech |
Entertainment |
Miscellaneous |
Features |
Classifieds |
Employment |
Index |
Home |
|
Science & Tech
| Previous
| Next
Successful test with diabetic baboon
DUKE UNIVERSITY Medical Centre researchers have reported that
specially encapsulated insulin-producing pancreas cells from pigs
have kept a diabetic baboon from needing insulin for more than
nine months. If this approach continues to show success in
similar experimental models, the researchers believe that trials
involving humans with insulin-dependant diabetes could begin
soon.
The researchers coated islet cells taken from pig pancreases with
a complex carbohydrate known as alginate and injected the
resulting spheres into the abdominal cavity of a diabetic baboon.
The cells reacted properly to changing levels of glucose in the
blood and secreted appropriate amounts of insulin to ensure
normal glucose metabolism.
Insulin, a hormone produced and secreted by specialized pancreas
cells called islets of Langerhans, converts sugars, starches and
other foods into the energy needed for everyday life. These
islets do not function properly in people with insulin-dependent,
or Type I, diabetes. These patients must have injected insulin to
stave off the long-term effects of improper glucose metabolism,
which includes blindness, kidney disease, heart disease, nerve
damage, limb loss and potentially death.
"After we confirmed that the baboon was indeed diabetic, we
surgically placed the encapsulated islets into the animal's
peritoneal cavity," said Dr. William Kendall senior surgical
resident at Duke who presented the results at the bi-annual
scientific meeting of the International Pancreas and Islet
Transplant Association at Innsbruck, Austria . The researchers
also prepared a poster session on the novel baboon model they
created for this study.
"To date, the animal's blood sugar levels have remained in the
normal range, and it hasn't required any additional islet cell
therapy," Kendall said. "We are very encouraged by these
results." Five more baboons are in various stages of study at
Duke.
According to Emmanuel Opara, associate research professor of
experimental surgery and cell biology at Duke University Medical
Centre, who began and leads Duke's islet cell transplant program,
this approach promises a practically unlimited supply of islet
cells that could put an end to the daily routine of multiple
insulin injections for the more than 1 million Americans with
Type I diabetes. Islet cell transplantation could also help
approximately one-quarter of the 15 million Americans with Type
II (adult onset) diabetes who require daily insulin injections.
A majority of people with Type II diabetes are not candidates for
islet cell transplants, since the root of their disorder is not
improper production of insulin, but rather the inability of
receptors in the body to properly process insulin.
"We envision being able to place these islets within the abdomen
of humans using existing laparoscopic, or minimally invasive,
techniques," Opara said. During the late 1990's, Opara's team
developed the technique to envelope the islets within an alginate
sphere. After isolating the insulin-producing islet cells from
the rest of the pig pancreas tissue, they are bathed in the
alginate solution and gently forced through a system that creates
a protective sphere around each islet.
"The spheres have surface pores that are large enough to allow
glucose to enter and insulin to exit, but are small enough to
keep immune system cells from entering the spheres and attacking
the islet cells," Opara said. "The spheres could be placed
anywhere in the body where they come into contact with blood or
other bodily fluids."
In the case of the first baboon, it required about 250,000 islets
taken from about three pigs. It is not yet known how many pig
pancreases would be needed to yield enough islets for a human.
Once the baboon became diabetic, its fasting glucose levels
jumped from about 100 milligrams per decaliter of blood to about
400 mg/dL. During the nine-month period following the islet cell
transplant, glucose levels averaged 115mg/dL. The researchers did
not detect any signs that the baboon's immune system reacted to
the pig islets. The pancreas is a complex gland it not only
regulates blood glucose levels, but also secretes enzymes that
are crucial to digestion. This complexity has led to difficulties
in developing a reliable animal model to study ways to treat the
disease.
The baboon model created by the Duke researchers is unique. - "We
took an approach that employed the best of both earlier attempts,
while avoiding the negative side effects of each," explained
Kendall. "First, we removed about 90 percent of the pancreas,
which left enough of the gland to maintain normal digestive
functions.
Then, we directly applied the streptozotocin to the remaining 10
percent of the pancreas during the operation - initially killing
the majority of remaining islets cells while minimizing the
systemic effects. We then administered additional small doses of
streptozotocin systemically, as needed, to destroy any residual
cells."
The researchers monitored an important biochemical marker to
demonstrate that it was indeed the pig islets, and not some
possibly surviving baboon islets, that were responsible for
producing the insulin. While in the pancreas, a precursor form of
insulin (proinsulin) is attached to a peptide known as C-peptide.
When this combined unit enters the bloodstream, it splits apart -
the insulin goes about its business of regulating glucose levels,
while the C-peptide travels through the liver to other tissues
where it may help with other physiological activities.
"For instance, we know that C-peptide can protect the
cardiovascular system from being damaged by the diabetes," Opara
said. "Patients with diabetes inject purified insulin, not the
complete proinsulin unit, and that is a reason why they must
watch the long-term complications of the disease. They do not
receive the C-peptide protection.
Send this article to Friends by E-Mail
|
|
Section : Science & Tech Previous : Glucose deficit affects young, old Next : Helping hand for the handicapped | |
|
Front Page |
National |
Southern States |
Other States |
International |
Opinion |
Business |
Sport |
Science & Tech |
Entertainment |
Miscellaneous |
Features |
Classifieds |
Employment |
Index |
Home | |
|
Copyrights © 2001 The Hindu Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu |
|